October 16, 2019
CancerNetwork® spoke with Dr. Peter Schmid about the KEYNOTE-522 trial.
April 07, 2017
In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.